A Phase 1 interventional study of Fulvestrant and Fulvestrant in Healthy, sponsored by Fresenius Kabi. Completed at 3 sites in Canada. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-09.
Sponsored by Fresenius Kabi · Phase 1, Interventional, and Other
The purpose of this study is to demonstrate bioequivalence between the test drug product, fulvestrant Injection, 50 mg/mL, and the Reference Listed Drug, Faslodex® Injection, 50 mg/mL.
This study is being conducted to establish bioequivalence between sponsor's test product [fulvestrant Injection, 50 mg/mL (Manufactured for Fresenius Kabi, USA)] and reference listed drug [Faslodex® Injection, 50 mg/mL, (Distributed by AstraZeneca Pharmaceuticals, USA] after intramuscular administration of a 250 mg dose (5 mL injection) into the upper outer quadrant of the right buttock to normal, healthy, nonsmoking post-menopausal female subjects.
The order of receiving the test product (T) or reference listed drug (R) for each subject during the study will be determined according to a randomization schedule.
Subjects will be allocated with a ratio of 1:1 to both treatment groups (i.e. T and R).
Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
5 mL intramuscular injection
Drug: Fulvestrant
5 mL intramuscular injection
Drug: Fulvestrant
Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
Also known as: Faslodex
Maximum observed plasma concentration
Time frame: 0-238 days
Area under the plasma concentration versus time curve (AUC0-238d) of fulvestrant
Time frame: 0-238 days
Area under the plasma concentration versus time curve (AUC0-28d) of fulvestrant
Time frame: 0-28 day
Area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUC0-t)
Time frame: 0-238 days
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC0-∞)
Time frame: 0-238 days
Time to Reach the Maximum Plasma Concentration (Tmax)
Time frame: 0-238 days
Elimination Half-life Period (t1/2)
Time frame: 0-238 days
Terminal Slope (λz)
Time frame: 0-238 days
Residual area in percentage (AUC_%Extrap_obs)
Time frame: 0-238 days
Injection site pain assessment
Time frame: 0-8 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fresenius Kabi